Medicolegal Review of Methotrexate Administration to Viable Intrauterine Pregnancies.

IF 0.2 4区 医学 Q4 Medicine 生殖医学杂志 Pub Date : 2017-03-01
Carlos A Garcia-Jasso, Gokhan S Kilic, Tony Wen, Russell R Snyder, Sangeeta Jain, John Y Phelps
{"title":"Medicolegal Review of Methotrexate Administration to Viable Intrauterine Pregnancies.","authors":"Carlos A Garcia-Jasso,&nbsp;Gokhan S Kilic,&nbsp;Tony Wen,&nbsp;Russell R Snyder,&nbsp;Sangeeta Jain,&nbsp;John Y Phelps","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To examine 3 legal cases in which physicians prescribed methotrexate to women with a viable intrauterine pregnancy, presumed to be ectopic, resulting in adverse fetal outcomes.</p><p><strong>Study design: </strong>We conducted an electronic literature search for legal cases using the keywords “methotrexate” and “pregnancy” in the LexisNexis legal research engine as well as an Internet-wide search using the additional keyword “verdict.” We manually searched the resultant list of identified cases and categorized the studies identified in the search by verdict, award amount, and outcome of the embryo exposed to methotrexate.</p><p><strong>Results: </strong>The monetary awards are typically greater when the embryo exposed to methotrexate lives and requires continuous medical and custodial care as compared to when the fetus dies in utero or shortly after birth.</p><p><strong>Conclusion: </strong>Physicians who, with all good intentions, prescribe methotrexate to women with a viable pregnancy, presumed to be ectopic, could find them-selves liable for an adverse fetal outcome. For the benefit of patients, their unborn offspring, and the liability exposure of the physician, it is important to be very cautious when prescribing methotrexate.</p>","PeriodicalId":50063,"journal":{"name":"生殖医学杂志","volume":"62 3-4","pages":"97-101"},"PeriodicalIF":0.2000,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"生殖医学杂志","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To examine 3 legal cases in which physicians prescribed methotrexate to women with a viable intrauterine pregnancy, presumed to be ectopic, resulting in adverse fetal outcomes.

Study design: We conducted an electronic literature search for legal cases using the keywords “methotrexate” and “pregnancy” in the LexisNexis legal research engine as well as an Internet-wide search using the additional keyword “verdict.” We manually searched the resultant list of identified cases and categorized the studies identified in the search by verdict, award amount, and outcome of the embryo exposed to methotrexate.

Results: The monetary awards are typically greater when the embryo exposed to methotrexate lives and requires continuous medical and custodial care as compared to when the fetus dies in utero or shortly after birth.

Conclusion: Physicians who, with all good intentions, prescribe methotrexate to women with a viable pregnancy, presumed to be ectopic, could find them-selves liable for an adverse fetal outcome. For the benefit of patients, their unborn offspring, and the liability exposure of the physician, it is important to be very cautious when prescribing methotrexate.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
甲氨蝶呤对存活宫内妊娠的药理学评价。
目的:探讨3例经推测为异位的可存活宫内妊娠妇女使用甲氨蝶呤导致不良胎儿结局的法律案例。研究设计:我们在LexisNexis法律研究引擎中使用关键词“甲氨蝶呤”和“怀孕”对法律案例进行了电子文献检索,并使用附加关键词“判决”在互联网范围内进行了搜索。我们手动检索了鉴定病例的结果列表,并根据判决、赔偿金额和胚胎暴露于甲氨蝶呤的结果对检索中鉴定的研究进行了分类。结果:与胎儿在子宫内或出生后不久死亡相比,接触甲氨蝶呤的胚胎存活并需要持续的医疗和监护时,金钱奖励通常更大。结论:医生,怀着良好的意图,处方甲氨蝶呤妇女可行妊娠,推测是异位,可能会发现自己负责不良胎儿结局。为了病人的利益,他们未出生的后代,以及医生的责任暴露,在开甲氨蝶呤处方时非常谨慎是很重要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
生殖医学杂志
生殖医学杂志 医学-妇产科学
自引率
0.00%
发文量
6427
审稿时长
6-12 weeks
期刊介绍: The Journal of Reproductive Medicine® has been the essential tool of Obstetricians and Gynecologists since 1968. As a highly regarded professional journal and the official periodical of six medical associations, JRM® brings timely and relevant information on the latest procedures and advances in the field of reproductive medicine. Published bimonthly, JRM® contains peer-reviewed articles and case reports submitted by top specialists. Common topics include research, clinical practice, and case reports related to general obstetrics and gynecology, infertility, female cancers, gynecologic surgery, contraception, and medical education.
期刊最新文献
Role of Capecitabine in the Management of Gestational Trophoblastic Neoplasia: A Drug for Two Settings. Comparison of Loop Electrosurgical Excision Procedure Using a Ring-Shaped Loop Versus a Right-Angled Triangular Loop. Gene Expression Analysis Identifies Common and Distinct Signatures Underlying Ductal and Lobular Breast Cancers. Analysis of Related Causes for No Embryos Transferred and Corresponding Coping Measures in Assisted Reproductive Technology. Cesarean Section Rates and Clinical Indications at a Large North African Hospital.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1